By Scott Murdoch
SYDNEY (Reuters) – Chinese medical research group WuXi XDC is set to price its shares at HK$20.6 each to raise $470 million in its Hong Kong IPO, according to two sources with direct knowledge of the matter.
The sources could not be named discussing confidential information.
WuXi XDC did not immediately respond to a request for comment.
The price is at the top of a HK$19.9 to HK$20.60 per share range flagged to investors when the deal was launched on Tuesday.
There were 178.4 million shares offered in the IPO.
At $470 million, WuXi XDC’s IPO is only the third largest to occur in Hong Kong in 2023 as new share sales in the city remain depressed as a result of higher interest rates and elevated global inflation.
WuXi XDC is a joint venture between WuXi Biologics and WuXi STA that provides end-to-end contract research services covering antibodies and other biologics intermediates.
(Reporting by Scott Murdoch; Editing by Muralikumar Anantharaman and Christopher Cushing)